{"id":"NCT01984697","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)","officialTitle":"A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-12","primaryCompletion":"2015-06-19","completion":"2017-07-24","firstPosted":"2013-11-15","resultsPosted":"2016-04-26","lastUpdate":"2018-08-08"},"enrollment":1518,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Human Papillomavirus Infection"],"interventions":[{"type":"BIOLOGICAL","name":"V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)","otherNames":[]}],"arms":[{"label":"Girls 9 to 14 Years V503 at Months 0 and 6","type":"EXPERIMENTAL"},{"label":"Boys 9 to 14 Years V503 at Months 0 and 6","type":"EXPERIMENTAL"},{"label":"Girls and Boys 9 to 14 Years V503 at Months 0 and 12","type":"EXPERIMENTAL"},{"label":"Girls 9 to 14 Years V503 at Months 0, 2, and 6","type":"EXPERIMENTAL"},{"label":"Young Women 16 to 26 Years V503 at Months 0, 2, and 6","type":"ACTIVE_COMPARATOR"}],"summary":"This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal was to establish that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that is not inferior to that observed in young women 16 to 26 years of age who received the standard 3-dose regimen of V503 (i.e., the population and dose regimen used to establish V503 efficacy).","primaryOutcome":{"measure":"Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen","timeFrame":"4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)","effectByArm":[{"arm":"Girls 9 to 14 Years V503 at Months 0 and 6","deltaMin":1657.9,"sd":null},{"arm":"Boys 9 to 14 Years V503 at Months 0 and 6","deltaMin":1557.4,"sd":null},{"arm":"Girls and Boys 9 to 14 Years V503 at Months 0 and 12","deltaMin":2678.8,"sd":null},{"arm":"Girls 9 to 14 Years V503 at Months 0, 2, and 6","deltaMin":1496.1,"sd":null},{"arm":"Young Women 16 to 26 Years V503 at Months 0, 2, and 6","deltaMin":770.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG001 vs OG004","p":"<0.001"},{"comp":"OG002 vs OG004","p":"<0.001"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27893068","39914257","33386332"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":294},"commonTop":["Injection site pain","Headache"]}}